Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (871)	2/4/2002 5:28:46 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 2243

"Vernalis is an integrated European biopharmaceutical company focused on the discovery, development and commercialisation of new prescription medicines for the treatment of diseases and disorders related to the central nervous system and is internationally recognised for its expertise in neuroscience. The Company’s most advanced product is frovatriptan which has been approved in both the US and Europe for the treatment of acute migraine. Frovatriptan has been licensed to Elan and Menarini who will be responsible for marketing the product in North America and Europe respectively. Under the terms of its licensing deals, Vernalis expects to receive further performance related milestone payments, in additional to royalty revenues exceeding 20% of global sales of frovatripan." vernalis.applejack.co.uk